For many women undergoing treatment for breast cancer – and some other cancers – chemical menopause is an unexpected and life-altering part of therapy. Unlike natural menopause, which unfolds gradually, treatment-induced menopause is sudden, often severe and layered on top of the physical and emotional demands of cancer care.
Why It Happens
Cancer treatments can abruptly shut down ovarian hormone production in several ways:
- Reduced hormone production by the body: aromatase inhibitors (e.g. anastrozole, letrozole) block the aromatase enzyme, which converts androgens into estrogen.
- Shutting down the ovaries:
a. LHRH/GnRH Agonists (e.g. goserelin, leuprolide) stop the brain from sending hormonal signals to the ovaries, creating a temporary medical menopause in premenopausal women.
b. Surgery or radiation permanently stop ovarian function by removing or irreversibly damaging the ovaries. - Blocking estrogen receptors: SERMs (e.g tamoxifen) block the cellular receptors that normally bind to estrogen, preventing it from having its normal effects on body tissues.
Emerging research suggests that sudden loss of estrogen also increases the firing of neurons in the brain that are responsible for hot flushes (also known as hot flashes) – explaining further why cancer treatments can make these symptoms even more severe.
Cancer treatment-induced menopause is not new. It is simply under-recognized. Women undergoing chemotherapy-induced menopause have long been known to experience more intense vasomotor symptoms, sleep disruption and cognitive changes than women going through natural menopause. (1) But awareness is changing. A recent consensus review published in the journal Menopause revealed that treatment-induced hormone deficiency is one of the most under-recognized drivers of symptom burden in breast-cancer survivors. (2)
And it’s not just about symptoms. Sudden loss of estrogen, progesterone, androgens can accelerate bone density loss and negatively impact cardiovascular health. These risks may progress more rapidly than they do in gradual, age-related menopause.
Treatment Options
Traditionally, menopause hormone therapy hasn’t been offered to breast cancer survivors (although views on this are evolving, and certain hormone treatments may sometimes be considered in consultation with an oncologist).
For women who cannot use systemic hormone therapy during or after cancer treatment, effective non-hormonal options exist. These include non-hormone medications approved specifically for the treatment of hot flushes (also known as hot flashes); cognitive behavioral therapy; or lifestyle interventions. These approaches can be combined and tailored to individual needs. It is also important to prioritize bone and cardiovascular health through appropriate screening, monitoring and specific treatment strategies. Early, proactive action helps to prevent complications and maintain long-term health and function.
Primary care physicians (most often) are not “menopause medicine” experts – by no fault of theirs. It is not taught in medical school and is definitely an emerging field. Therefore, patients need to look for a provider that specializes and is experienced in this type of care. And, hopefully one that takes health insurance. Working with the oncologist, APP or oncology navigator is always a good starting point for these discussions. They must be had!
Genitourinary Syndrome of Menopause (GSM): A Treatable Concern
GSM – vaginal dryness, burning, pain with intercourse/during a routine pelvic exam, urinary urgency and recurrent UTIs – is more common and more severe in chemical menopause. Vaginal estrogen therapy restores genitourinary health, reduces discomfort with intercourse, improves irritative urinary symptoms and significantly reduces the risk of bladder infections (UTIs). (3) Current evidence supports the safety of low dose vaginal estrogen for most breast-cancer survivors. (4) Non-estrogen options – moisturizers, lubricants, hyaluronic acid, vaginal DHEA – can help, but vaginal estrogen remains the most effective treatment for GSM.
The symptoms of chemical menopause don’t always happen right away or all at once – they can sneak up over time – even many years later depending on the patient’s age. Cancer survivors often tell us that no one has ever talked to them about GSM or other symptoms that may occur and what to expect “down the road”. These topics can be quite embarrassing to bring up, and the last thing a cancer patient/survivor wants is the frightening thought that “something else” has gone wrong. These patients have already been through a lot – rigorous treatment, hair loss, mastectomy, lumpectomy, reconstruction, and “enough is enough”. So, they just deal with the symptoms – until they can’t. Unfortunately, by the time they get to Urology of Indiana, they may be suffering significantly.
What You Can Do
- Track symptoms to identify patterns and triggers
- Ask about non-hormonal options for hot flashes, sleep and mood
- Discuss GSM treatment, including the safety of vaginal estrogen
- Protect bone health with DEXA scans, exercise, calcium, vitamin D and medications when appropriate
- Prioritize exercise and heart health. If you’ve not exercised before, find a professional that specializes in menopausal women and/or cancer patients/survivors to prevent injury.
- Seek menopause-specialist support to navigate complex decisions
Chemical menopause is challenging – but being proactive with education and evidence-based care, women can regain comfort, confidence and control during and after cancer treatment.
References
(1) Mar-Fan H et al. Ann Oncol; 21(5):983-987, 2010
(2) Glynne S, et al. Menopause; 33(1):88-117, 2026.
(3) Kaufman MR et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol; 214(3): 242-250, 2025.
(4) Mitchel O et al. J Clin Oncol;43(16 Suppl): 578, 2025.